Molecular Characterisation of Macbecin as an Hsp90 Inhibitor
Martin, C.J., Gaisser, S., Challis, I.R., Carletti, I., Wilkinson, B., Gregory, M., Prodromou, C., Roe, S.M., Pearl, L.H., Boyd, S.M., Zhang, M.Q.(2008) J Med Chem 51: 2853
- PubMed: 18357975 
- DOI: https://doi.org/10.1021/jm701558c
- Primary Citation of Related Structures:  
2VWC - PubMed Abstract: 
Macbecin compares favorably to geldanamycin as an Hsp90 inhibitor, being more soluble, stable, more potently inhibiting ATPase activity (IC50 = 2 microM) and binding with higher affinity (Kd = 0.24 microM). Structural studies reveal significant differences in their Hsp90 binding characteristics, and macbecin-induced tumor cell growth inhibition is accompanied by characteristic degradation of Hsp90 client proteins. Macbecin significantly reduced tumor growth rates (minimum T/C: 32%) in a DU145 murine xenograft. Macbecin thus represents an attractive lead for further optimization.
Organizational Affiliation: 
Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K. [email protected]